C81.42
Lymphocyte-rich Hodgkin lymphoma, intrathoracic lymph nodes
Clinical Classification Guidelines
Medical Intelligence & Overview
Lymphocyte-rich Hodgkin lymphoma is a subtype of Hodgkin lymphoma, a cancer that originates in the lymphatic system. This particular form is characterized by an abundance of lymphocytes and primarily affects the intrathoracic lymph nodes, which are located within the chest cavity. Recognizing this specific diagnosis helps guide appropriate medical management and provides insight into the disease's nature and progression.
Causes & Symptoms
Clinical Causes: Genetic mutations that influence immune cell behavior Viral infections, such as Epstein-Barr virus, which have been associated with Hodgkin lymphoma Environmental exposures to certain chemicals or toxins Weakened immune system, either due to other illnesses or immunosuppressive treatments
Key Symptoms: Swelling or painless enlargement of lymph nodes in the chest Persistent cough or chest discomfort Shortness of breath or difficulty breathing Unexplained weight loss Night sweats and fever Fatigue and general malaise
Diagnostic & Treatment
Diagnosis Path: Diagnosing lymphocyte-rich Hodgkin lymphoma involves a combination of clinical evaluation and diagnostic tests. A biopsy of the affected lymph node is essential, allowing microscopic examination to identify characteristic Reed-Sternberg cells and lymphocyte patterns. Imaging studies such as CT scans or PET scans help determine the extent and distribution of the disease. Blood tests may be performed to assess overall health and organ function, while additional tests might include bone marrow biopsy or laboratory markers specific to Hodgkin lymphoma.
Treatment Protocols: Treatment strategies for this subtype of Hodgkin lymphoma typically involve chemotherapy protocols designed to target rapidly dividing cancer cells. In some cases, radiation therapy may be applied to affected areas within the chest. The selection of treatment depends on the stage of the disease, overall health, and specific features of the lymphoma. Advances in targeted therapies and immunotherapy are also emerging options. Regular monitoring through follow-up imaging and clinical assessments is crucial for evaluating treatment response and managing potential side effects.
Clinical Advice & FAQs
Billing Guidance
Is C81.42 a billable ICD-10 code?
Yes, C81.42 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C81.42?
Clinical documentation must specify the nature of Lymphocyte-rich Hodgkin lymphoma, intrathoracic lymph nodes and any associated comorbidities for accurate reporting.
Cite this Clinical Reference